Title: Transcription profiling of Kawasaki disease patients treated with aspirin and IV immunoglobulins. Some patients were also treated with methylprednisone. [original title: Transcription profiling of Kawasaki disease patients who may benefit from methylprednisolone]
Organism(s): Homo sapiens
Description: All patients received 30 mg/kg aspirin per day during the acute stage of illness and 5 mg/kg per day after defervescence. Patients were divided into 2 groups. Group B (11 patients) was predicted to be resistant (Egami score ? 3) to IV immunoglobulins (IVIG); Group A consisted of 6 randomly-selected patients with Egami scores ? 2 and thus predicted to be IVIG-responsive. Among Group B, 6 patients received IVIG treatment, and 5 also received IV methylprednisone. [original description: Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Intravenous immunoglobulin (IVIG) treatment-resistant patients are high risk of developing coronary artery lesions (CALs) with Kawasaki disease (KD). The IVIG-responsive (Group A; n = 6) and -resistant patients (Group B) were predicted before starting the initial treatment using the Egami scoring system, and randomly allocated a single-IVIG treatment group (Group B1; n = 6) or a IVIG-plus-methylprednisolone (IVMP) combined therapy group (Group B2; n = 5). We investigated transcript abundance in the leukocytes of those patients using microarray analysis. Results: five patients in Group A and 1 patient in Group B1 responded to initial IVIG treatment. All Group B2 patients responded to IVIP-plus-IVMP combined therapy. Prior to performing these treatments, those transcripts related to IVIG-resistance and to the development of CALs, such as IL1R, IL18R, oncostatin M, suppressor of cytokine signaling-3, S100A12 protein, carcinoembryonic antigen-related cell adhesion molecule-1, matrix metallopeptidase-9 and polycythemia rubra vera-1 were more abundant in Group B patients in comparison to Group A patients. Moreover, those transcripts in Group B2 patients were more profoundly and broadly suppressed than Group B1 patients after treatment. Conclusion: this study elucidated the molecular mechanism of the effectiveness of IVIG-plus-IVMP combined therapy. 34 samples of pre- and post-treatment in three groups consisting of predicted as IVIG-responsive patients, given single-IVIG treatment patients and IVIG-plus-IVMP combined therapy group in predicted as IVIG-resistant patients. Samples were analyzed without replicates.]
Design(s): transcription profiling by array
Experimental factor(s):
NSAID treatment
2 recorded
control condition acetylsalicylic acid
clinical treatment
3 recorded
none intravenous immunoglobulin intravenous immunoglobulin and methylprednisolone
2 recorded
intravenous immunoglobulin resistant (predicted) intravenous immunoglobulin responsive (predicted)
IVMP treatment
2 recorded
control condition 6alpha-methylprednisolone
IVIG treatment
2 recorded
control condition Immunoglobulins, Intravenous
Publication(s): Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y, Sato K, Minoura K, Kokubo K, Kobayashi H, Ishii M.
Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. PubMed:19680167

Sample attribute(s):
patient number
6 recorded
3 6 2 1 5 4
Material Type
2 recorded
total_RNA unknown
1 recorded
Treatment group
3 recorded
B1 A B2
organism part
1 recorded
peripheral blood
organism part 2
1 recorded
venous blood
1 recorded
disease state
1 recorded
Kawasaki disease
1 recorded
Homo sapiens
ethnic group
1 recorded
Contact(s): Masahiro IshiiYayoi NakahataKastunori MinouraKayoko SatoHirosuke KobayashiKeiko NomotoShohei OgataKazumasa AkiyamaKenichi KokuboYoshihito Ogihara
Release Date: 7/8/2010
Submission Date:
Metadata Downloads Download Study Metadata as ISAtabDownload Study Metadata as ISAtab
Assay Downloads
transcription profiling using DNA microarray
34 assays